Enhanced Antitumor Immunity following Neoadjuvant Chemoradiotherapy Mediates a Favourable Prognosis in Women with Resected Pancreatic Cancer

Scientists investigated sex disparities in clinical outcomes and tumor immune profiles in patients with PDAC who underwent upfront resection or resection preceded by gemcitabine-based neoadjuvant chemoradiotherapy.